SENP3 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:26168, HGNC:17862, MIM:612844, NM_015670, NP_056485, SENP3, SMT3IP1, SSP3, SUMO specific peptidase 3, Ulp1

Omim:OMIM:612844

Id:ENSG00000161956

Hgnc:HGNC:17862

Entrez:26168

Ensembl:ENSG00000161956

Description:SUMO specific peptidase 3

The reversible posttranslational modification of proteins by the addition of small ubiquitin-like SUMO proteins (see SUMO1; MIM 601912) is required for numerous biologic processes. SUMO-specific proteases, such as SENP3, are responsible for the initial processing of SUMO precursors to generate a C-terminal diglycine motif required for the conjugation reaction. They also have isopeptidase activity for the removal of SUMO from high molecular mass SUMO conjugates (Di Bacco et al., 2006 [PubMed 16738315]).[supplied by OMIM, Jun 2009]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SENP3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SENP3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SENP3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SENP3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SENP3.

Results found

Linked to

	Label	Description
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE132369,GSE132371 3 V 0 CCCP HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 4 PALMITIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 9 V 13 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 10 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 gemcitabine 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125782 3 V 1 GLUTAMINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE132369,GSE132371 3 V 0 CCCP HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 4 PALMITIC ACID HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 9 V 13 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 10 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE165548 gemcitabine 2 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE125782 3 V 1 GLUTAMINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.